All News

Lindsay Diamond, AGNP-C, AOCNP, is, in a word, selfless.

The Food and Drug Administration approved Imfinzi plus gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer.

Cancer is talked about more openly nowadays, and while watching a movie with my daughter, a scene portraying a character in hospice care gave me flashbacks to our cancer experience.

ATX01, a new topical treatment for chemotherapy-induced peripheral neuropathy, will be investigated in a phase 2 trial.

From “Good Morning America” host Robin Roberts stepping away from the show after her partner finished breast cancer radiation to a former Tampa Bay Buccaneer dying of leukemia, here is what’s happening in the cancer space this week.

After learning that I had Lynch syndrome and a MLH1 mutation, I changed my lifestyle to hopefully prevent a cancer diagnosis.

CURE® surveyed its audience to see what good habits they have picked up since being diagnosed with cancer. Here’s what they had to say.

The last year was tough, but with a new cancer treatment center and other opportunities, I’m going to sit tight and bloom where planted.

Delivering Sarclisa via an under-the-skin injection may improve the quality of life of patients with pretreated relapsed, refractory multiple myeloma, according to recent research.

Patients with blastic plasmacytoid dendritic cell neoplasms can enroll in the ongoing CADENZA trial, which is investigating the safety and efficacy of the novel agent pivekimab sunirine in patients with the rare blood cancer.

The FDA’s decision allows patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome — types of blood cancer — to continue enrolling on the TakeAim Leukemia trial.

Even though I had no symptoms, my prostate cancer was caught thanks to frequent follow-ups with my doctor.

Patients with early-stage rectal cancer may be able to forego major surgery — thus preserving their organs and quality of life — with a pre-surgical chemotherapy regimen, according to recent study results.

The first patient has been treated with H002, a novel drug being investigated for non-small cell lung cancer that is resistant to a prior EGFR TKI treatment.

Patients with breast cancer who received post-mastectomy breast reconstruction had similar recurrence rates regardless of the timing of their reconstructive surgery, according to recent study findings.

An expert explains the different types of kidney cancer surgeries, and what patients can expect to experience after the procedure.

I’m giving cancer’s “battle language” an update and focusing my survivorship plan on emotional wellbeing and honesty.

Researchers developed an artificial intelligence algorithm to potentially improve the prediction of colon cancer recurrence, which may help patients receive the appropriate treatment.

A clinical trial recently kicked off, analyzing the combination of imetelstat plus Jakafi for the treatment of myelofibrosis, a type of rare blood cancer.

I recently was asked to speak at a banquet for my cancer center and saw that as a great opportunity to recognize those who cared for me.

Firefighters and recovery workers exposed to the aftermath of 9/11 in New York City had a higher occurrence of MGUS, a condition which may progress to myeloma, according to recent research.

I'm no longer the "helpless patient with cancer," though sometimes I need a reminder to keep myself in check.

Long-term follow-up shows that treatment with Empliciti plus pomalidomide and dexamethasone continues to significantly increase survival rates in patients with relapsed or refractory multiple myeloma, a persistent cancer affecting white blood cells that may be resistant to treatment.

Lisa’s excellent fund of knowledge, experience in oncology, outstanding judgment and interest in learning all make her a truly outstanding clinician.

Moreen is a tireless advocate for our patients, ensuring that all receive timely and compassionate care.

Many participants enrolled in the CRC-PREVENT trial are from communities often underrepresented in clinical trials due to gender, race and socioeconomic status, among other factors.

After being homebound for two years from the COVID-19 pandemic, I was eager to get out, though I did have many cancer/COVID-19 concerns.